All In Biotech

Drug Trial Radar · NCT05039931

A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Solid Tumors

An Open-Label, Multi-Center, Phase I Study to Evaluate the Safety, Tolerability,Pharmacokinetic/Pharmacodynamics and Anti-tumor Activity of Tetra-specific Antibody GNC-035 in Participants With Locally Advanced or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jul 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Sep 15, 2021

Primary completion

Jun 2023

Study completion Jun 2023

Sponsor

Sponsor type
Industry
Collaborators
SystImmune Inc.
First posted
Sep 10, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this study, the safety, tolerability and preliminary effectiveness of GNC-035 in participants with locally advanced or metastatic solid tumors will be investigated to assess the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum administered dose (MAD) for MTD is not reached of GNC-035.

Conditions

  • Breast Cancer
  • Solid Tumor

Interventions

  • GNC-035Drug

    Administration by intravenous infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. DLTTime frame: Up to 2 weeks
  2. MTD or MADTime frame: Up to 2 weeks
  3. TEAETime frame: Up to 2 years
  4. The recommended dose for future clinical studyTime frame: Up to 2 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • West China Hospital of Sichuan University

    Sichuan, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.